12:00 AM
Jan 23, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Fabrazyme agalsidase beta regulatory update

Sanofi's Genzyme Corp. unit said EMA approved its Framingham, Mass., manufacturing facility for the production of Fabry's disease therapy Fabrazyme agalsidase beta....

Read the full 98 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >